Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04047979 · ClinicalTrials.gov registry record · Phase 2
Systems Biology of Zoster Vaccine
A Phase 2 study of Shingles and Zoster, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT04047979 is a Phase 2 study of Shingles and Zoster that has completed, run by Emory University. The registered enrollment target is 38 participants, below the 393-participant average among 6 other Shingles trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04047979, a Phase 2 study of Shingles and Zoster, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). The study will be looking at certain markers in the blood after vaccination with Shingrix®.
Conditions Studied
Interventions
- BIOLOGICAL Shingrix®
Study Locations (1)
Georgia
- The Hope Clinic - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-11-14 |
| Est. Completion | 2023-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04047979
The ClinicalTrials.gov registry entry for NCT04047979 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 6 other Shingles trials with a reported enrollment target (90% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Shingles appearing as the primary indexed condition, and to 1 intervention - of which Shingrix® is the first listed.
NCT04047979 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04047979 about?
NCT04047979 is a clinical study titled "Systems Biology of Zoster Vaccine". The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). The study will be looking at certain markers in the blood after vaccination with Shingrix®.
What is the current status of trial NCT04047979?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2019-11-14. Estimated completion is 2023-10-30.
What conditions does trial NCT04047979 study?
This clinical trial studies the following conditions: Shingles, Zoster, Zoster Varicella, Chicken Pox.
What interventions are being tested in trial NCT04047979?
The interventions under investigation include: Shingrix® (BIOLOGICAL).
Who is sponsoring clinical trial NCT04047979?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04047979 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shingles
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
RECRUITING · Phase 2
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
ACTIVE NOT RECRUITING · Phase 2
-
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
COMPLETED · Phase 1
-
Valacyclovir in Immunocompromised Children
COMPLETED · Phase 1
-
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.